Table 4 Factors associated with high warfarin dosage in patients administered warfarin at Korle-bu Teaching Hospital in Accra
From: Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population
Characteristic | Dosage classification | Crude OR [95% CI] | p value | Adjusted OR [95% CI]a | p value | |
|---|---|---|---|---|---|---|
High | Low | |||||
N = 57 | N = 84 | |||||
n, % | n, % | |||||
Age (years) (median, interquartile range) | 46 (33.0–57.0) | 48 (36.8–59.0) | 0.99 [0.96–1.01] | 0.298 | 0.99 [0.96–1.03] | 0.770 |
Warfarin duration (months) (median, interquartile range) | 24 (11–99) | 24 (8–61) | 1.00 [1.00–1.01] | 0.062 | 1.01 [1.00–1.02] | 0.033 |
Gender | ||||||
Female | 33 (57.9) | 46 (54.8) | 1.14 [0.58–2.24] | 0.713 | 1.05 [0.40–2.71] | 0.928 |
Male | 24 (42.1) | 38 (45.2) | 1.00 | |||
Body mass index | ||||||
Overweight | 33 (57.9) | 53 (63.1) | 0.80 [0.40–1.60] | 0.535 | – | – |
Normal | 24 (42.1) | 31 (36.9) | 1.00 | |||
Diagnosis | ||||||
Deep vein thrombosis | 21 (936.8) | 30 (36.2) | 1.00 [0.47–2.11] | 0.992 | – | – |
Atrial fibrillation | 2 (3.5) | 8 (9.6) | 0.36 [0.07–1.81] | 0.214 | – | – |
Pulmonary embolism | 8 (14.1) | 8 (9.6) | 1.42 [0.47–4.28] | 0.530 | – | – |
Mistral valve replacement | 26 (45.6) | 37 (44.6) | 1.00 | |||
Presence of side effects | ||||||
Yes | 11 (19.3) | 16 (19.1) | 1.02 [0.43–2.39] | 0.970 | – | – |
No | 46 (80.7) | 68 (80.9) | 1.00 | |||
Other medications given | ||||||
Yes | 30 (52.6) | 46 (54.8) | 0.92 [0.47–1.80] | 0.803 | – | – |
No | 27 (47.4) | 38 (45.2) | 1.00 | |||
VKORC1 | ||||||
GA (heterozygous) | 1 (2.6) | 11 (19.0) | 0.12 [0.01–0.94] | 0.043 | 0.06 [0.01–0.63] | 0.019 |
GG (Wild type) | 37 (97.4) | 47 (81.0) | 1.00 | 1.00 | ||
CYP4F2 | ||||||
TT (mutant) | 5 (9.6) | 3 (4.7) | 3 [0.59–15.26] | 0.186 | 5.47 [0.61–48.79] | 0.128 |
CT (heterozygous) | 37 (71.2) | 43 (67.2) | 1.55 [0.64–3.77] | 0.335 | 1.91 [0.54–6.80] | 0.317 |
CC (wild type) | 10 (19.2) | 18 (28.1) | 1.00 | 1.00 | ||